Text Size

Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00346008
First received: June 27, 2006
Last updated: February 18, 2009
Last verified: December 2008
History of Changes
  Purpose

RATIONALE: Studying the genes expressed in samples of blood from patients with cancer and their family members may help doctors identify biomarkers related to cancer.

PURPOSE: This clinical trial is studying genes to identify melanoma in patients in Iceland and their family members.


Condition Intervention
Melanoma (Skin)
 Genetic: mutation analysis
Other: high performance liquid chromatography
Other: laboratory biomarker analysis
Other: questionnaire administration

Study Type: Observational
Official Title: Genetic Epidemiologic Studies of Melanoma in Iceland

Resource links provided by NLM:

MedlinePlus related topics: Cancer Melanoma
U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Feasibility to identify melanoma [ Designated as safety issue: No ]
  • Feasibility to detect mutation [ Designated as safety issue: No ]
  • Ability to create datasets [ Designated as safety issue: No ]

Estimated Enrollment: 2500
Study Start Date: October 2005
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • Assess the feasibility of Iceland Genomics Corporation (UVS) to identify melanoma in multiple-case families, individuals with multiple tumors, and selected additional family members in Iceland.
  • Assess the feasibility of mutation detection using sequencing and HPLC.
  • Determine UVS' ability to create datasets with demographic, epidemiologic and molecular data.

OUTLINE: Participants and patients undergo blood collection and complete lifestyle questionnaires. All patients and population-based controls have DNA samples sequenced for MC1R. Demographic and epidemiologic data on all study participants is collected. Sequencing of the major melanoma susceptibility genes CFDKN2A, CDK4, and MC1R is also performed.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

DISEASE CHARACTERISTICS:

  • Patients diagnosed with melanoma and selected family members are eligible to participate
  • Must live in Iceland

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00346008

Locations
Iceland
Iceland Genomics Corporation
Reykjavik, Iceland, 105
Sponsors and Collaborators
Iceland Genomics Corporation
National Cancer Institute (NCI)
Investigators
Study Chair: Alisa Goldstein, PhD National Cancer Institute (NCI)
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier: NCT00346008     History of Changes
Obsolete Identifiers: NCT00482534
Other Study ID Numbers: CDR0000551606, NCI-06-C-N026, NBCI-03-033-CM, NBCI-01-087-CM, 999906026
Study First Received: June 27, 2006
Last Updated: February 18, 2009
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
melanoma
recurrent melanoma
stage I melanoma
 stage II melanoma
stage III melanoma
stage IV melanoma

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
 Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas

ClinicalTrials.gov processed this record on May 16, 2013